Dr Reddy s Laboratories Ltd, Appili Therapeutics and Global Response Aid FZCO (GRA) on Tuesday announced that Dr Reddy s Canada has filed an application on behalf of the consortium for Reeqonus (favipiravir) tablets for acute treatment of mild to moderate COVID-19 adult patients. The application has been filed under Health Canada s Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19, Hyderabad-headquartered pharma major Dr Reddy s said in a statement. In September, the interim order was signed by Canada s Minister of Health to create a new authorisation pathway that will help expedite the authorisation of drugs and vaccines for COVID-19.
Dr Reddy s seeks approval from Health Canada for Favipiravir financialexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialexpress.com Daily Mail and Mail on Sunday newspapers.
Representational image.
Dr. Reddy s is working closely with Health Canada for an expedited review of the drug application, says Vinod Ramachandran, Vice President and General Manager, Dr. Reddy’s Laboratories Canada Inc
Dr Reddy s Laboratories Ltd, Canada-based Appili Therapeutics and Dubai-based Global Response Aid FZCO (GRA) on Tuesday said Dr Reddy s Canada has filed an application on behalf of the consortium for Reeqonus (favipiravir) Tablets for treating COVID-19 in the North American country.
The application was filed under Health Canada s Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19, a release from the city-based drug maker said.
Dr Reddy s seeks approval for Covid drug in Canada
By IANS |
Published on
Tue, Dec 22 2020 12:57 IST |
0 Views
US coronavirus death toll mounts to 6, Trump wants vaccine at âmaximum speedâ.. Image Source: IANS News
Hyderabad, Dec 22 : Dr Reddy s Laboratories Ltd, Appili Therapeutics and Global Response Aid FZCO (GRA) on Tuesday announced that Dr Reddy s Canada has filed an application on behalf of the consortium for Reeqonus (favipiravir) tablets for acute treatment of mild to moderate COVID-19 adult patients.
The application has been filed under Health Canada s Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19, Hyderabad-headquartered pharma major Dr Reddy s said in a statement.
Reuters
Published: 19 Dec 2020 11:16 AM BdST
Updated: 19 Dec 2020 11:36 AM BdST A specialist demonstrates a vial containing Gam-COVID-Vac, also known as Sputnik-V, vaccine against the coronavirus disease (COVID-19) at a production facility of BIOCAD biotechnology company in Saint Petersburg, Russia December 4, 2020. REUTERS/Anton Vaganov/Files
India s coronavirus tally breached the 10 million mark on Saturday, the world s second highest, even though the number of new daily cases has fallen sharply since a mid-September peak. );
}
India will produce about 300 million doses of Russia s Sputnik V coronavirus vaccines next year, a Russian official was quoted as saying, nearly three times the previously known number as deals have been signed with more manufacturers.